Arnuity Ellipta (Fluticasone Furoate) Patent Expiration, LOE Window & CMS Spending
Arnuity Ellipta (Fluticasone Furoate) by GSK: FDA Orange Book LOE 2026-03-01, 12 AB generics, $231.0M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | GSK |
| FDA Application & Pathway | N205625 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2026-03-01 |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 12 |
| 2024 CMS Total Public Spend | $231.0M |
| 2024 Medicare Part D Spend | $199.9M |
| 2024 Medicaid Spend | $31.2M |
| Reported Wholesale Price Change (CA SB 17) | 5 WAC filings (max 16.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.